Health equity company Acclinate announced it raised $7 million in Series A funding, led by Cencora Ventures and with notable contributions from Labcorp and Latimer Ventures. This funding round will enable Acclinate to scale its impact on clinical trial diversity and health equity.
Acclinate focuses on driving diversity in clinical trials. Its community engagement platform, trusted by top pharmaceutical brands, helps make existing trials more inclusive and plan more diverse studies in the future.
Cencora Ventures (formerly AB Health Ventures) is the corporate venture fund originally started by AmerisourceBergen before becoming Cencora, a leader in global healthcare solutions. This fund invests and provides commercial support to emerging healthcare startup companies and brings unparalleled expertise and resources to this strategic partnership.
This funding round will also help drive Acclinate’s expansion and enhance its Enhanced Diversity in Clinical Trials (e-DICT) platform. As Acclinate continues to innovate initiatives aimed at inclusivity and equity in healthcare, this funding round propels its goals forward.
KEY QUOTE:
“This investment marks a significant milestone for Acclinate and underscores our commitment to revolutionizing health equity and clinical trial diversity at a larger scale. With the backing of prominent healthcare organizations like Cencora and Labcorp, we are poised to accelerate tangible change in the healthcare industry and empower diverse communities to proactively manage their health.”
- Del Smith, CEO and Co-Founder of Acclinate
